TURNOVER (x1000 NOK)
NET PROFIT (x1000 NOK)
EMPLOYEES
Fujirebio Diagnostics AB
Closing information (x1000 NOK)
| Closing information | 2023/03 (consolidated) | 2022/03 (consolidated) | 2021/03 (consolidated) |
| Turnover |
246,685
|
244,614 | |
| Financial expenses |
441
|
28,568 | |
| Earnings before taxes |
129,675
|
98,340 | |
| EBITDA |
134,665
|
131,360 | |
| Total assets |
572,462
|
454,713 | |
| Current assets |
276,319
|
389,193 | |
| Current liabilities |
59,135
|
27,626 | |
| Equity capital |
507,107
|
421,909 | |
| - share capital |
596
|
627 | |
| Employees (average) |
86
|
75
|
71 |
Financial ratios
| Fiscal year | 2023/03 (consolidated) | 2022/03 (consolidated) | 2021/03 (consolidated) |
| Solvency |
88.6%
|
92.8% | |
| Turnover per employee |
3,289
|
3,445 | |
| Profit as a percentage of turnover |
52.6%
|
40.2% | |
| Return on assets (ROA) |
22.7%
|
27.9% | |
| Current ratio |
467.3%
|
1408.8% | |
| Return on equity (ROE) |
25.6%
|
23.3% | |
| Change turnover |
13,874
|
-24,665 | |
| Change turnover % |
17%
|
6%
|
-9% |
| Chg. No. of employees |
11
|
4
|
4 |
| Chg. No. of employees % |
15%
|
6%
|
6% |
Total value of public sale
| Fiscal year | 2023/03 (consolidated) | 2022/03 (consolidated) | 2021/03 (consolidated) |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.